MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap. In 2016, the Company filed a patent covering the treatment of various ...

Annovis Bio (NYSE:ANVS) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson’s treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson’s, helping them retain and improve both motor and non-motor activities and cognitive functions.According to the data, buntanetap showed statistically significant improvements in cognitive ability in the overall population of Parkinson’s patients ...

Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson's patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the MDS-UPDRS Part II, Part III, Part II+III and Total scores in Parkinson's patients with a >3-year diagnosis. Buntanetap showed the same statistical improvement in MDS-UPDRS Part II, Part III, Part II+III and Total scores in Parkinson's p ...

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3 ...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed ...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed ...

MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: July 2, 2024, 4:30pm ET.Register Today: ...

Core Insights - Annovis Bio Inc. announced significant efficacy and safety results from its Phase II/III Alzheimer's study of Buntanetap, showing improvements in both APOE4 carriers and non-carriers [1][2][3] Efficacy Findings - Buntanetap demonstrated a statistically significant dose-response in early Alzheimer's patients, with a -3.3 points improvement in ADAS-Cog11 scores over baseline and -2.3 points improvement from placebo [1] - In APOE4 carriers treated with 15mg Buntanetap, there was a -3.15 improvement in ADAS-Cog11 scores [2] Safety Profile - Buntanetap exhibited comparable safety in both APOE4 carriers and non-carriers, with no instances of Amyloid-Related Imaging Abnormalities (ARIA) reported [2][3] - The study included 159 APOE4 carriers (33 homozygotes and 126 heterozygotes) and 159 non-carriers, highlighting the diverse patient population [2] Scientific Context - Recent findings in Nature Medicine have redefined APOE4 homozygosity as a distinct genetic form of Alzheimer's, indicating a need for tailored prevention strategies and treatments [2] - Dr. Samuel Gandy noted the heightened safety risks associated with anti-amyloid drugs for APOE4 homozygotes, contrasting with Buntanetap's safety profile [3] Future Development Plans - Annovis Bio plans to initiate an 18-month Phase III trial focusing on biomarker-positive early Alzheimer's patients to further validate Buntanetap's efficacy and safety [4] - The upcoming investor call will provide detailed findings and outline future development plans for Buntanetap [4] Company Overview - Annovis Bio Inc. is dedicated to developing therapies for neurodegenerative diseases, targeting multiple neurotoxic proteins to restore brain function and improve patient quality of life [5]

MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: June 11, 2024, 4:30pm ET.Register Today ...

Shares of Annovis Bio, Inc. (ANVS) have gained 0.1% over the past four weeks to close the last trading session at $7.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $33.50 indicates a potential upside of 359.5%.The average comprises four short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $26.26. While the lowest estimate indicat ...